Polyclonal T-cell antigens

Polyclonal T-cell antigens refer to a broad collection of surface proteins expressed on T-lymphocytes and thymocytes, including CD2, CD3, CD4, CD8, CD11a, CD18, CD25, CD44, CD45, and HLA molecules (Mohty, 2002, Leukemia). These antigens serve as the collective target for polyclonal antibody preparations such as antithymocyte globulin (ATG), which are used to induce profound immunosuppression (StatPearls, 2023). The biological functions of these targeted antigens are diverse, encompassing signal transduction, cell-to-cell adhesion, and antigen recognition, all of which are vital for T-cell-mediated immunity (DrugBank, DB00033). In therapeutic contexts, targeting these antigens is primarily indicated for the prevention and treatment of acute organ transplant rejection, graft-versus-host disease (GVHD), and severe aplastic anemia (PubMed, PMID: 11840282). Drugs interacting with these antigens facilitate T-cell depletion through complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and the induction of apoptosis (NIH, LiverTox). While highly effective at suppressing the immune system, the broad targeting of these antigens can lead to significant safety issues, including cytokine release syndrome, serum sickness, and a heightened risk of opportunistic infections (FDA, Thymoglobulin Label).

Other names

T-lymphocyte surface antigensThymocyte antigensT-cell surface markersT-lymphocyte antigens

Depletion of T-lymphocytes via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, alongside the modulation of surface receptors to inhibit T-cell activation and trafficking.